TEMPO Is Not Another Pilot — It Is the Commercial Infrastructure for Digital Health Scale
The history of digital health regulation in the United States is littered with cleared devices that never achieved commercial adoption because the reimbursement pathway did not exist when the regulatory clearance was granted. The FDA's January 2026 updated guidance on general wellness products and clinical decision support software addressed the classification question — clarifying which digital health products require regulatory oversight and which do not. TEMPO addresses the commercial question that classification clarity does not resolve: how does a digital health company get paid by the largest single healthcare payer in the United States for a device that has been cleared by the FDA but has no established Medicare billing code? TEMPO creates a structured pathway for exactly this problem. Devices admitted to the pilot receive coverage under the ACCESS model, generate outcomes data in real Medicare patient populations, and produce the evidence base that CMS needs to establish permanent coverage and payment rates. For a digital therapeutic or remote monitoring device with a Medicare-eligible patient population, TEMPO participation is worth substantially more than the coverage revenue it generates during the pilot period.
The January 2026 FDA guidance update that preceded the TEMPO launch contains a detail that most coverage buried in the broader classification clarifications: the guidance's expanded treatment of wearable and sensor-based products that estimate physiologic parameters explicitly acknowledges that some products generating clinically relevant outputs can qualify as general wellness products rather than regulated medical devices, as long as outputs are framed for wellness rather than diagnostic purposes. This creates a product development and regulatory strategy opportunity that the TEMPO pilot makes commercially viable. A company can design a wearable platform with a wellness-framed general release that avoids the 510(k) pathway, generate real-world evidence in a large consumer population, and then use that evidence base to support a separate clinically-framed product submission for TEMPO participation with a Medicare-specific indication. The companies that are designing both tracks simultaneously — consumer wellness and Medicare clinical — are building the regulatory and evidence architecture for sustainable commercial scale in a way that single-track strategies cannot replicate.
The AI TPLC Draft and LLM Governance Guidance Are the Forward-Looking Risk Variables
The IntuitionLabs analysis of FDA's 2026 digital health guidance identifies two upcoming regulatory developments that will reshape AI-enabled device development timelines: the pending final guidance on the AI Total Product Lifecycle framework, and new policies on large language models in healthcare tools. The AI TPLC guidance will establish the change control standards for AI-enabled medical devices — essentially, how much a device's AI can adapt after market authorization before triggering a new regulatory submission. This is the most commercially consequential unresolved question in digital health regulation, because the value proposition of AI-enabled medical devices depends on continuous learning and improvement. A restrictive TPLC standard that treats every performance update as a new device submission would make continuous-learning AI devices commercially nonviable. A permissive standard creates new risk profiles that FDA's current adverse event monitoring systems are not designed to track. The position FDA takes in the final TPLC guidance will define the product architecture constraints for every AI-enabled device entering the 510(k) or De Novo pathway for the next decade.
The LLM governance question sits in a different risk category. Large language models used as clinical decision support tools — summarizing patient records, generating differential diagnoses, drafting clinical notes — are being deployed in healthcare settings today without clear FDA regulatory classification in most use configurations. The four-criteria test that exempts CDS software from device regulation under the 21st Century Cures Act was written before LLMs existed as a clinical tool category. FDA's advisory committee discussions on AI oversight and cybersecurity in 2025 and early 2026 have signaled that the agency intends to provide classification guidance for LLM-based clinical tools within the current year. Companies currently deploying LLMs in clinical contexts without FDA regulatory classification are operating in a window that FDA's forthcoming guidance will close — and the companies that have proactively characterized their LLM tools against the existing four-criteria framework are best positioned to navigate whatever classification standard the agency establishes.